Search company, investor...

Predict your next investment

Celgene company logo
Corporation
HEALTHCARE | Drug Development
celgene.com

Investments

96

Portfolio Exits

45

Partners & Customers

10

About Celgene

Celgene is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. On November 21, 2019, Celgene was acquired by Bristol-Myers Squibb.

Headquarters Location

86 Morris Avenue

Summit, New Jersey, 07901,

United States

908-673-9000

Want to inform investors similar to Celgene about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Celgene

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Celgene in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Research containing Celgene

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Celgene in 2 CB Insights research briefs, most recently on Jun 2, 2022.

Latest Celgene News

Gene Therapy Market Report (2022 to 2030) - Novartis AG, Spark Therapeutics Inc. (Roche), Gilead Sciences Inc., Biogen Inc., Avita Medical, Jazz Pharmaceuticals Plc. and Celgene Corporation

Jan 25, 2023

Udaipur, INDIA 20 Maxwell House, Singapore, Jan. 25, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global gene therapy market is expected to clock US$ 4.64 billion by 2030 and to grow at a CAGR of 8.1% during the forecast period. Gene therapy focuses on cell reprogramming to provide a novel remedy/treatment method for a disease by replacing the damaged gene. This sort of treatment shows promising outcomes for a variety of diseases or disorders, including heart disease, hemophilia/acquired hemophilia, cancer, and many more. Gene therapy has several uses, the most important of which is the development of vaccines for various infectious or chronic illnesses. This exclusive information is published by Growth Plus Reports in its report titled “Gene Therapy Market – Global Outlook & Forecast 2022-2030” Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/gene-therapy-market/8079 Market Drivers The market's expansion can be attributed to the rising prevalence of chronic diseases such as cancer, central nervous system disease, metabolic disorders, cardiovascular disease, and so on. Additionally, the growing R&D activity has resulted in the continuously increasing introduction of innovative products/therapies and the enhancement of the product pipeline. Furthermore, rising financings such as IPOs (initial public offerings), venture capital financing, follow-on financing, and expanding partnerships and acquisitions significantly influence market growth. For instance, in 2022, Bayer AG and Mammoth Biosciences Inc. announced a strategic collaboration for the development of novel in-vivo gene editing technology. Bayer's gene therapy platform is strengthened further and Mammoth's vision of unlocking the full potential of novel CRISPR systems is also being supported. Additionally, Mammoth is expected to receive an upfront payment of USD 40 million, with potential future payments of more than a billion USD upon successful achievement. The gene therapy market has been analyzed from four perspectives: vector type, delivery type, application, end-users, and region. Excerpts from ‘By Vector Type Segmentation’ The vector type in the global gene therapy market has been bifurcated into: Viral Non-Viral Non-viral vector has the largest revenue share in the market as this is a safer treatment approach with a cheap cost, making it accessible to those with limited financial resources. This segment also possesses a high gene capacity, a low immunogenic response, a high transfection efficiency, and the ability to be chemically adaptable. Furthermore, rising cancer and other targeted illness cases and increased funding in gene therapy also contribute to the growth of this segment, thereby propelling the gene therapy market. While viral vectors are the most effective in gene therapy, they offer limited applications as a result of the limitation of chemical flexibility, thus depicting a steady growth during the projected timeline. Excerpts from ‘By Region Segmentation’ Geographically, the global gene therapy market has been segmented into: North America

Celgene Investments

96 Investments

Celgene has made 96 investments. Their latest investment was in Cyteir Therapeutics as part of their Series B - II on October 10, 2019.

CBI Logo

Celgene Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/15/2019

Series B - II

Cyteir Therapeutics

$40.2M

No

4

9/11/2019

Series B

Anokion

$40M

No

9

8/28/2019

Partnership - II

Immatics Biotechnologies

$75M

Yes

5

8/20/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

6/18/2019

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/15/2019

9/11/2019

8/28/2019

8/20/2019

6/18/2019

Round

Series B - II

Series B

Partnership - II

Series B

Series B - II

Company

Cyteir Therapeutics

Anokion

Immatics Biotechnologies

Subscribe to see more

Subscribe to see more

Amount

$40.2M

$40M

$75M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

9

5

10

10

Celgene Portfolio Exits

45 Portfolio Exits

Celgene has 45 portfolio exits. Their latest portfolio exit was Human Longevity on June 21, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/21/2022

Acq - Pending

$99M

1

10/1/2021

IPO

$99M

Public

3

9/21/2021

Acquired

$99M

2

8/18/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

8/5/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/21/2022

10/1/2021

9/21/2021

8/18/2021

8/5/2021

Exit

Acq - Pending

IPO

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

3

2

10

10

Celgene Acquisitions

14 Acquisitions

Celgene acquired 14 companies. Their latest acquisition was Juno Therapeutics on March 06, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/6/2018

Series B

$99M

$310M

Acq - P2P

5

1/8/2018

Debt

$99M

$112.5M

Acquired

3

2/14/2017

Series A

$99M

$105.5M

Acquired

1

1/26/2017

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/2/2016

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

3/6/2018

1/8/2018

2/14/2017

1/26/2017

12/2/2016

Investment Stage

Series B

Debt

Series A

Series A

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$310M

$112.5M

$105.5M

$99M

$99M

Note

Acq - P2P

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

5

3

1

10

10

Celgene Partners & Customers

10 Partners and customers

Celgene has 10 strategic partners and customers. Celgene recently partnered with Theranos on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/30/2021

Partner

United States

Former Celgene scientist says partnership with Theranos ended over poor test quality - MassDevice

Former Celgene scientist says partnership with Theranos ended over poor test quality .

1

1/19/2021

Partner

United States

Recombinant Antibody Network Partners with Bristol Myers Squibb to Develop Novel Therapies.

The ongoing partnership with Bristol Myers Squibb will enable the Recombinant Antibody Network to continue to develop and apply the latest technologies for the discovery of new cell-surface targets and the selection of clinically promising antibodies , as well as to expand research collaboration with the disease biology communities at the three universities .

1

10/18/2020

Partner

United States

Global anti-epilepsy drugs market Competitive Trends, Business Statictics, Industry Revenue and Forecast 2023

In October 2016 , Abbott has collaborated with Celgene and Agios for diagnostic identification of IDH mutations .

1

3/25/2020

Partner

United States

Subscribe to see more

Subscribe to see more

10

1/10/2020

Licensor

United States

Subscribe to see more

Subscribe to see more

10

Date

9/30/2021

1/19/2021

10/18/2020

3/25/2020

1/10/2020

Type

Partner

Partner

Partner

Partner

Licensor

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Former Celgene scientist says partnership with Theranos ended over poor test quality - MassDevice

Former Celgene scientist says partnership with Theranos ended over poor test quality .

Recombinant Antibody Network Partners with Bristol Myers Squibb to Develop Novel Therapies.

The ongoing partnership with Bristol Myers Squibb will enable the Recombinant Antibody Network to continue to develop and apply the latest technologies for the discovery of new cell-surface targets and the selection of clinically promising antibodies , as well as to expand research collaboration with the disease biology communities at the three universities .

Global anti-epilepsy drugs market Competitive Trends, Business Statictics, Industry Revenue and Forecast 2023

In October 2016 , Abbott has collaborated with Celgene and Agios for diagnostic identification of IDH mutations .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Celgene Team

33 Team Members

Celgene has 33 team members, including , .

Name

Work History

Title

Status

Sheila DeWitt

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Sheila DeWitt

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Celgene to Competitors

B
BRAVIS

BRAVIS is a software and system house. It develops high-end internet-based video conference systems.

Pfizer Logo
Pfizer

Pfizer (NYSE: PFE) offers a diversified health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. It works across various markets to promote wellness, prevention, treatments, and cures that challenge feared diseases. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. The company was founded in 1849 and is based in New York, New York.

FoodMarble Logo
FoodMarble

FoodMarble has developed a personal digestive tracker. Based on validated clinical technology, this tiny breath test device and app can be used with the help of AI to help people work out what foods are most compatible with their unique digestive system.

Civica Rx Logo
Civica Rx

Civica Rx is a not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving generic medications.

Syntr Health Technologies Logo
Syntr Health Technologies

Syntr Health Technologies specializes in the micro fragmentation of adipose tissue for body contouring. The company was founded in 2016 and is based in Irvine, California.

H
HAPLN Science

HAPLN Science is a drug development company that focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company's products include treatments for degenerative arthritis, skin aging treatment, hair loss, and connective tissue disease. HAPLN Science was founded in 2018 and is based in Seongnam, South Korea.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.